10-Q: Bio-Techne Reports Flat Sales, Lower Earnings in Q2 Amid Restructuring

Bio-Techne's second-quarter results show flat sales and decreased earnings, impacted by restructuring and acquisition costs.

Summary

• Bio-Techne's net sales for the quarter ended December 31, 2023, remained flat at $272.6 million compared to the same period last year.
• Net earnings attributable to Bio-Techne decreased to $27.5 million for the quarter, down from $50.0 million in the prior year.
• The company's six-month net sales increased by 2% to $549.5 million, while net earnings decreased to $78.5 million from $139.6 million.
• Organic revenue declined by 2% for the quarter, with acquisitions and foreign currency exchange having a positive impact of 1% each.
• Gross margins for the quarter were 64.8%, down from 67.5% in the prior year, and 65.8% for the six months, down from 67.1% in the prior year.
• The company incurred restructuring charges and an impairment of assets held-for-sale, impacting profitability.
• The acquisition of Lunaphore Technologies SA for $169.7 million also contributed to the lower earnings.
• The company's Protein Sciences segment saw a decrease in sales, while the Diagnostics and Genomics segment experienced growth.
• The company's effective tax rate was 17.7% for the quarter and 5.4% for the six months, influenced by discrete tax items.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like growth in the Diagnostics and Genomics segment and strategic acquisitions, but the overall sentiment is negative due to decreased earnings, declining organic revenue, and reduced gross margins. The restructuring and impairment charges also contribute to the negative sentiment.

Positives

• The Diagnostics and Genomics segment experienced an 11% increase in sales for the quarter.
• Acquisitions and foreign currency exchange had a positive impact on revenue.
• The company generated $142.5 million in cash from operating activities for the six months ended December 31, 2023.
• The company has $553 million available on its line of credit.

Negatives

• Net earnings attributable to Bio-Techne decreased significantly for both the quarter and six-month periods.
• Organic revenue declined by 2% for the quarter.
• Gross margins decreased for both the quarter and six-month periods.
• The company incurred significant restructuring charges and an impairment of assets held-for-sale.
• The Protein Sciences segment experienced a decrease in sales.
• The acquisition of Lunaphore negatively impacted the operating margin of the Diagnostics and Genomics segment.

Risks

• The company is exposed to fluctuations in foreign currency exchange rates.
• The company faces risks related to the integration of newly acquired businesses.
• The company is subject to increased competition.
• The company relies on internal manufacturing and related operations, which could be disrupted.
• The company faces supply chain challenges.
• The company is subject to governmental regulation.
• The company must maintain its intellectual property rights.
• The company faces credit risk and fluctuations in the market value of its investment portfolio.
• The company could experience delays and expenses related to facility construction and improvements.

Future Outlook

The company expects capital expenditures for the remainder of fiscal 2024 to be approximately $26 million. The company expects the consolidated income tax rate for the remainder of fiscal 2024 to range from 23% to 27%, excluding the impact of discrete items. The company is currently forecasting the second option payment of approximately $1 billion plus potential contingent consideration to occur between fiscal 2026 and fiscal 2028 related to the Wilson Wolf acquisition.

Management Comments

• Management expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future.
• Management is focused on recovering operating margins, optimizing distribution, and enhancing organizational efficiency.

Industry Context

The company's performance reflects broader trends in the biotechnology and diagnostics industries, including the impact of economic conditions on customer spending and the ongoing importance of strategic acquisitions for growth. The company's focus on spatial biology aligns with a growing area of interest in the research and clinical markets.

Comparison to Industry Standards

• Bio-Techne's gross margin of 64.8% for the quarter is lower than some of its peers in the life sciences industry, which often report gross margins in the 70-80% range. For example, companies like Thermo Fisher Scientific and Danaher often achieve higher gross margins due to their scale and diversified product portfolios.
• The company's operating margin of 14% for the quarter is also lower than some of its peers, which can achieve operating margins in the 20-30% range. This is partly due to the restructuring costs and acquisition-related expenses that Bio-Techne incurred during the quarter.
• The company's organic revenue decline of 2% for the quarter is a concern, as many of its peers are experiencing organic growth in the mid-single digits or higher. This suggests that Bio-Techne may be facing some challenges in its core business.
• The acquisition of Lunaphore Technologies SA is a strategic move to expand into the spatial biology market, which is a high-growth area. However, the acquisition has negatively impacted the company's operating margin in the short term.
• The company's investment in Wilson Wolf Corporation is a significant long-term investment, but the timing of the second option payment is uncertain and could impact the company's cash flow in the future.

Management Changes

Legal Proceedings

• As of February 7, 2024, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

Stakeholder Impact

• Shareholders may be concerned about the decrease in earnings and the decline in organic revenue.
• Employees may be affected by the ongoing restructuring efforts.
• Customers may be impacted by changes in the company's product portfolio and service offerings.
• Suppliers may be affected by changes in the company's supply chain.
• Creditors may be impacted by the company's debt levels and financial performance.

Next Steps

• The company will continue to implement its restructuring plan.
• The company will focus on integrating the Lunaphore acquisition.
• The company will continue to monitor its financial performance and make adjustments as needed.
• The company will continue to invest in strategic growth areas.

Key Dates

Keywords

Bio-Techne, financial results, quarterly report, restructuring, acquisitions, Lunaphore, Protein Sciences, Diagnostics and Genomics, revenue, earnings, gross margin, operating margin, impairment, organic growth